Predictive Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Predictive Oncology şirketinin toplam hissedar öz sermayesi $4.1M ve toplam borcu $276.9K olup, bu da borç-öz sermaye oranını 6.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.6M ve $6.5M dir.

Anahtar bilgiler

6.8%

Borç/özkaynak oranı

US$276.93k

Borç

Faiz karşılama oranı	n/a
Nakit	US$5.33m
Eşitlik	US$4.09m
Toplam yükümlülükler	US$6.49m
Toplam varlıklar	US$10.59m

Son finansal sağlık güncellemeleri

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

Recent updates

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: POAI 'nin kısa vadeli varlıkları ( $6.9M ) kısa vadeli yükümlülüklerini ( $4.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: POAI şirketinin kısa vadeli varlıkları ( $6.9M ) uzun vadeli yükümlülüklerini ( $1.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: POAI şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: POAI 'nin borç/öz sermaye oranı son 5 yılda 17.1% seviyesinden 6.8% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: POAI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: POAI un, serbest nakit akışı her yıl % 13.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Predictive Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Predictive Oncology Inc. Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.98 loss in 2Q 2023)

Predictive Oncology Inc. Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Inc. to Report Q2, 2024 Results on Aug 14, 2024

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Share price stability

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.86 loss in 1Q 2023)

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Share price stability

New major risk - Market cap size

Full year 2023 earnings released: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$1.04 loss in 3Q 2022)

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$3.02 loss in 2Q 2022)

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

First quarter 2023 earnings released: US$0.86 loss per share (vs US$1.02 loss in 1Q 2022)

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Price target increased to US$5.00

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology has a new CEO

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Predictive Oncology announces retirement of CEO Mel Engle

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought US$62k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$4.50

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

CEO & Director Carl Schwartz has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.